Imatinib for the adjuvant treatment of gastrointestinal stromal tumours

NICE technology appraisals [TA196] Published date:

NICE does not recommend imatinib as an adjuvant treatment for people after surgical removal of a GIST.

There is not enough evidence from clinical trials to say how well imatinib works as an adjuvant treatment, or whether it works well enough to justify its cost, so NICE did not recommend it.

Results from some clinical trials of imatinib as an adjuvant treatment after surgical removal of a GIST are due soon, and NICE will look at this evidence when it becomes available.

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.

Get involved